Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Parasitol ; 95(3): 652-5, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19642802

RESUMEN

Cases of visceral leishmaniasis (VL) in the course of human immunodeficiency virus (HIV) infection have regularly been recorded, mainly in southern Europe. HIV infection can increase the risk of VL development by 10-100 times in endemic areas. We describe the occurrence of this co-infection in 15 patients from Brazil. The mean age of the patients was 38 +/- 8.8 yr, with 86.6% males. The mean time between HIV diagnosis and the onset of visceral leishmaniasis was 44 +/- 39 mo. The main signs and symptoms presented at admission were splenomegaly (73%), weight loss (73%), cough (67%), fever (67%), asthenia (60%), and diarrhea (60%). The mean T CD4+ lymphocyte count was 173.7 +/- 225.6 cells/mm3, and viral load was 51,030 +/- 133,737/mm3. Treatment consisted of pentavalent antimonials (67% of cases). Most (87%) patients recovered from VL infection; death occurred in 1 patient due to septic shock. VL is an important opportunistic infection in HIV patients, which is potentially fatal, even when correct treatment is completed. Treatment should be done with pentavalent antimonials or amphotericin B in the case of relapse. Although there is no consensus, secondary prophylaxis should be considered in severe cases.


Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/epidemiología , Infecciones por VIH/complicaciones , Leishmaniasis Visceral/complicaciones , Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Infecciones Oportunistas Relacionadas con el SIDA/parasitología , Adulto , Anfotericina B/uso terapéutico , Antiprotozoarios/uso terapéutico , Terapia Antirretroviral Altamente Activa , Astenia , Médula Ósea/parasitología , Brasil/epidemiología , Recuento de Linfocito CD4 , Tos , Diarrea , Femenino , Fiebre , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/epidemiología , Humanos , Leishmaniasis Visceral/tratamiento farmacológico , Leishmaniasis Visceral/epidemiología , Masculino , Meglumina/uso terapéutico , Antimoniato de Meglumina , Persona de Mediana Edad , Compuestos Organometálicos/uso terapéutico , Pancitopenia , Estudios Retrospectivos , Esplenomegalia , Factores de Tiempo , Pérdida de Peso
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA